Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.52 |
| ▸ | CTSK | P43235 | 8/20 | 0.52 |
| ▸ | CTSL | P07711 | 7/20 | 0.52 |
| ▸ | CTSB | P07858 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP7 | P09237 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350533 | 1.00 | CTSS (0.52) | CTSSCTSKCTSLCTSBL3MBTL1 | |
| SCHEMBL14932686 | 1.00 | CTSS (0.52) | CTSSCTSKCTSLCTSBL3MBTL1 | |
| SCHEMBL5277957 | 1.00 | CTSS (0.52) | CTSSCTSKCTSLCTSBL3MBTL1 | |
| SCHEMBL7344740 | 0.80 | CTSS (0.47) | CTSSCTSKCTSLCTSBMMP1 | |
| SCHEMBL7337277 | 0.78 | CTSK (0.59) | CTSSCTSKCTSLCTSB | |
| SCHEMBL31086879 | 0.75 | CTSL (0.62) | CTSSCTSKCTSLCTSBMMP1 | |
| SCHEMBL9054077 | 0.74 | CTSS (0.60) | CTSSCTSKCTSLCTSBL3MBTL1 | |
| SCHEMBL7370421 | 0.74 | CTSK (0.45) | CTSSCTSKCTSLREN | |
| SCHEMBL9227916 | 0.74 | CTSK (0.45) | CTSSCTSKCTSLREN | |
| SCHEMBL7343508 | 0.74 | CTSK (0.45) | CTSSCTSKCTSLREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024153744-A1 | AUTOPHAGY ACTIVATORS FOR THE TREATMENT OF RHABDOMYOLYSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-07-25 | — | — | WO | claimed |
| WO-2024018245-A1 | USE OF CALPAIN INHIBITORS FOR THE TREATMENT OF THE DIABETIC KIDNEY DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-01-25 | — | — | WO | claimed |
| US-20220370463-A1 | STABILIZED C-FMS INTRACELLULAR FRAGMENTS (FICD) PROMOTE OSTEOCLAST DIFFERENTIATION AND ARTHRITIC BONE EROSION | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY | 2022-11-24 | — | — | US | claimed |
| EP-3969913-A1 | BIOMARKER FOR ASSESSMENT OF SPINAL CORD INJURY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-03-23 | — | — | EP | claimed |
| US-20240279710-A1 | FLUORESCENT PROBES | TOHOKU TECHNO ARCH CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| WO-2024153744-A1 | AUTOPHAGY ACTIVATORS FOR THE TREATMENT OF RHABDOMYOLYSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-07-25 | — | — | WO | disclosed |
| EP-4361166-A1 | FLUORESCENT PROBES | Tohoku Techno Arch Co., Ltd. (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-117480175-A | Fluorescent probe | 东北泰克诺亚奇股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2024018245-A1 | USE OF CALPAIN INHIBITORS FOR THE TREATMENT OF THE DIABETIC KIDNEY DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-01-25 | — | — | WO | disclosed |
| WO-2022270607-A1 | FLUORESCENT PROBES | 株式会社 東北テクノアーチ | 2022-12-29 | — | — | WO | disclosed |
| US-20220370463-A1 | STABILIZED C-FMS INTRACELLULAR FRAGMENTS (FICD) PROMOTE OSTEOCLAST DIFFERENTIATION AND ARTHRITIC BONE EROSION | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY | 2022-11-24 | — | — | US | disclosed |
| EP-4031160-A1 | STABILIZED C-FMS INTRACELLULAR FRAGMENTS (FICD) PROMOTE OSTEOCLAST DIFFERENTIATION AND ARTHRITIC BONE EROSION | New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special Surgery (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-3969913-A1 | BIOMARKER FOR ASSESSMENT OF SPINAL CORD INJURY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-03-23 | — | — | EP | disclosed |
| JP-2007246518-A | CRYSTAL OF CYCLOPROPENONE COMPOUND | MITSUBISHI PHARMA CORP | 2007-09-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279710-A1 | FLUORESCENT PROBES | CAPN1, CAPN2, CAPNS1 | CTSS 146/4885CTSK 91/4885CTSL 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.